In conclusion, our study indicated that male patients had substantially worse prognosis than female patients among all patients with mutSMARCA4 and among the NSCLC subgroup, suggesting that poor prognosis of SMARCA4-mutated malignancies observed in other studies may be primarily driven by male patients. Here, SMARCA4 is linked to non-small cell lung carcinoma.